The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

In studies where CD20-targeted CAR T cells were shown effective in patients with B-cell lymphomas, they were also shown to activate and recognize malignant cells even when antigen expression was low.

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta ...

Odronextamab is an investigational bispecific antibody that binds to CD20 expressed on the surface of B cells, and to CD3 receptor expressed on the surface of T cells. This results in local T-cell ...

Janssen has retained its rights to develop and commercialize B-cell targeting CD28 bispecific antibodies, including JNJ-9401 (PSMA x CD28) and JNJ-1493 (CD20 x CD28). "Plamotamab is a Phase 2 ...

“CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.” Croatian Medical Journal: “Therapies for multiple sclerosis targeting B cells.” National Multiple ...

In addition to studying T cells, the researchers identified a role for CD20 + B lymphocytes, a less commonly discussed immune cell type in melanoma. About 22% of the tumors contained these B cells ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...